UNSPSC 51111848: Formestane

This classification denotes a steroidal aromatase inhibitor with the molecular formula C19H26O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PUB9T8T355, chemically known as 4-hydroxyandrost-4-ene-3,17-dione but generally known as formestane, which bears US NIH Compound Identifier 11273. European Medicines Agency schedules Formestane in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07784MIG.

UNSPSC 51111848 Formestane, a Commodity code, covers generic pharmaceutical products and over-the-counter medications that state and local health systems, purchasing cooperatives, and institutional buyers procure through established pharmaceutical supply chains. State and local entities buying under this code typically source through cooperative purchasing vehicles and authorized wholesale distributors rather than directly from manufacturers, with purchasing coordinated through multistate alliances, state health departments, and institutional pharmacy systems serving hospitals, clinics, long-term care facilities, and correctional institutions.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (S1070000015802) on January 20, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon, with proposals due March 26, 2026. Vendors must supply through three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencara, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC), maintain relationships with at least two, hold cGMP certification and DSCSA compliance, and demonstrate pricing flexibility through flat price, net price formats (NF30, NF60, NF90), or WAC-minus structures. Evaluation emphasizes price competitiveness (75 percent), with secondary weight on fixed pricing for the contract term (10 percent), price compliance formatting (5 percent), EDI capability (5 percent), and agreement to a 3 percent administrative fee (5 percent). The contract runs two years for new vendors and aligns through June 30, 2028, for incumbents, with performance penalties ranging from $200 to $1,500 per violation for late reporting, missed onboarding, or improper class-of-trade denials.